Association of aldosterone with left ventricular mass in hypertension: Interaction with plasma fibrinogen levels

American Journal of Hypertension

Volumn 26, Issue 1, 2013, Pages 111-117

  Catena, Cristiana ^a   Colussi, Gianluca ^a   Valeri, Marica ^a   Sechi, Leonardo A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

aldosterone; blood pressure; D dimer; fibrinogen; hemostatic system; hypertension; left ventricular hypertrophy; plasminogen activator inhibitor 1; prothrombotic state

Indexed keywords

ALDOSTERONE; D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

ADULT; AGE DISTRIBUTION; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 84876579886     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hps006     Document Type: Article

References (43)

1. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated hypertension. Ann Intern Med 1991;114:345-352.
2. Drazner MH. The progression of hypertensive heart disease. Circulation 2011;123:327-334.
3. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002;40:23-27. (Pubitemid 34755974)
4. Kozàkovà M, Buralli S, Palombo C, Bernini G, Moretti A, Favilla S, Taddei S, Salvetti A. Myocardial ultrasound backscatter in hypertension. Relation to aldosterone and endothelium. Hypertension 2003;41:230-236. (Pubitemid 36204894)
5. Catena C, Colussi GL, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralcorticoid antagonism in patients with primary aldosteronism. Hypertension 2007;50:911-918. (Pubitemid 350287534)
6. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008;52:529-534.
7. Yoshida C, Goda A, Naito Y, Nakaboh A, Matsumoto M, Otsuka M, Ohyanagi M, Hirotani S, Lee-Kawataba M, Tsujino T, Masuyama T. Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. J Hypertension 2001;29:357-363.
8. Nakahara T, Takata Y, Hirayama Y, Asano K, Adachi H, Shiokawa G, Sumi T, Ogawa T, Yamashina A. Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagene type III amino-terminal peptide. Circ J 2007;71:716-721. (Pubitemid 46683363)
9. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ, Vasan RS. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008;118:2252-2258.
10. Stewart AD, Millasseau SC, Dawes M, Kyd PA, Chambers JB, Ritter JM, Chowienczyk PJ. Aldosterone and left ventricular hypertrophy in Afro-Caribbean subjects with low renin hypertension. Am J Hypertens 2006;19:19-24. (Pubitemid 43217028)
11. Mulè G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C, Palermo A, Andronico G, Cerasola G. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with metabolic syndrome. Am J Hypertens 2008;21:1055-1061.
12. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with target organ damage in hypertension. Hypertension 2000;36:978-985.
13. Catena C, Novello M, Lapenna R, Baroselli S, Colussi G, Nadalini E, Favret G, Cavarape A, Soardo G, Sechi LA. New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). J Hypertens 2005;23:1617-1631. (Pubitemid 41233418)
14. Palmieri V, Celentano A, Roman MJ, de Simone G, Lewis MR, Best L, Lee ET, Robbins DC, Howard BV, Devereux RB. Fibrinogen and preclinical echocardiographic target organ damage: the Strong Heart Study. Hypertension 2001;38:1068-1074. (Pubitemid 34252807)
15. Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemoreology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997;80:1566-1571. (Pubitemid 28011832)
16. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BW, Devereux RB. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the Strong Heart Study. Diabetes Care 2003;26:2764-2769. (Pubitemid 37205544)
17. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G, Buemi M. Fibrinogen, inflammation 12 and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 2003;33:561-566. (Pubitemid 36783215)
18. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 2003;9:1715-1732. (Pubitemid 36958345)
19. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006;19:1293-1299.
20. Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ. Differing effects of mineralocorticoid receptor-dependent and-independent potassium-sparing diuretics on fibrinolytic balance. Hypertension 2005;46:313-320. (Pubitemid 41099163)
21. Sechi LA, Novello M, Colussi GL, Di Fabio A, Chiuch A, Nadalini E, Casanova-Borca A, Uzzau A, Catena C. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008;21:1347-1353.
22. Mancia G, De Backer G, Dominczak A, Cifkova R, Fagard R, Germanò G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A;ESC-ESC task force on the management of arterial hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 2007;25:1751-1762. (Pubitemid 47356612)
23. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA 1997;277:1689-1695. (Pubitemid 27232743)
24. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low-renin hypertensive states. Trends Endocrinol Metab 2005;16:86-91. (Pubitemid 40432456)
25. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458. (Pubitemid 16119719)
26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Stewart WJ. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiography 2005:18:1440-1463.
27. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi W. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force for the nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-184.
28. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133.
29. Schroeder AP, Sihm I, Morn B, Thygesen K, Pedersen EB, Lederballe O. Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Am J Hypertens 1996;9:207-215. (Pubitemid 26121271)
30. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 2008;13:367-375.
31. Catena C, Colussi GL, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res 2012;44:181-187.
32. Schunkert H, Hense HW, Muschill M, Luchner A, Kurzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997;77:24-31. (Pubitemid 27076910)
33. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PW. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004;43:957-962. (Pubitemid 38579898)
34. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krazuse S, Burns D, Williams GH. Effects of eplerenone, enalalpril, and eplerenone/enelapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108:1831-1838. (Pubitemid 37296092)
35. Catena C, Colussi GL, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res 2012;44:188-193.
36. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-505. (Pubitemid 14059351)
37. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96:1102-1108. (Pubitemid 27344210)
38. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med 1993;118:956-963. (Pubitemid 23164134)
39. Arentt DK, McClelland RL, Bank A, Bluemke DA, Cushman M, Szalai AJ, Jain N, Gomes AS, Heckbert SR, Hundley WG, Lima JA. Biomarkers of inflammation and hemostasis associated with left ventricular mass: the multiethnic study of atherosclerosis (MESA). Int J Epidemiol Genet 2011;2:391-400.
40. Diamantopoulos EJ, Andreadis EA, Vassilopoulos CV, Theodorides TG, Giannakopoulos NS, Chatzis NA, Christopoulou-Kokkinou VD. Increased plasma plasminogen activator inhibitor-1 levels: possible marker of hypertensive organ damage. Clin Exp Hypertens 2003;25:1-9. (Pubitemid 36194015)
41. Rosello-Lleti E, Rivera M, Martinez-DOlz L, Gonzalez Juanatey JR, Cortes R, Jordan A, Morillas P, Lauwers C, Calabuig JR, Antorrena I, de rivas B, Portoles M, Bertomeu V. Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens 2009;22:444-450.
42. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000;275:5760-5766. (Pubitemid 30115219)
43. Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S. Critical role of apoptosis signalregulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 2009;54:544-551.